UCB asks Euros to OK Cimzia for arthritis; Cipla patents new forms of Nexium, Fosamax

> Belgium's UCB asked European regulators to approve its autoimmune-disorder med Cimzia for treatment of rheumatoid arthritis; it's already FDA-approved for use in Crohn's disease. Report

> Cipla received product patents in India for new forms of the blockbuster drugs Nexium, a heartburn treatment from AstraZeneca, and Fosamax, Merck's osteoporosis med. Report

> Sweden's Orexo got an approval recommendation from Europe's Committee for Medicinal Products for Human Use for Rapinyl, a drug for breakthrough cancer pain. Report

> Unilife Medical Solutions inked a five-year, $16.4 million global licensing agreement with Sanofi-Aventis for its ready-to-fill syringe product. Report

> China's vertically integrated Yongxin Pharmaceuticals signed a 10-year franchise deal with an unnamed U.S. drug chain to operate stores in Jilin Province. Report

> Eli Lilly will pay $64,400 to settle a lawsuit charging severance pay was withheld from a long-time employee ito force her to withdraw a discrimination charge. Report

> A new test that can detect multiple-drug-resistant tuberculosis in two days instead of the standard two to three months promises to help significantly improve treatment and prevent the spread of the airborne infection. Report

> A closely watched Alzheimer's drug being developed by H. Lundbeck and its U.S. partner Myriad Genetics failed a crucial late-stage study, sending shares of Lundbeck down to a four-year low and triggering a decision to axe the development program. Flurizan report

> ThromboGenics is touting data from a Phase IIb trial of microplasmin for vitreous injection, saying it resolved the underlying disease in close to a third of all patients in one dosage group without the need of a vitrectomy. ThromboGenics report

> ZymoGenetics has lined up $100 million in fresh financing from Deerfield Management. ZymoGenetics report

> The FDA has rejected Labopharm's appeal of the regulators' decision on once-daily tramadol, but kept the door open to an approval. Report

> The Wall Street Journal offers more bleak assessments from the pharma industry on their ability to win an FDA approval for a new therapy. Report

> Anyone looking for fresh signs of the faltering state of the U.K.'s biotech industry need look no further than Ardana. Unable to engineer a speedy refinancing, sale or merger, the Scottish developer--a specialist in reproductive health--brought in the administrators to run the company and suspended trading of its shares. Report

And Finally... Another reason to eat salmon: Low levels of "good" cholesterol are associated with poor memory, researchers found. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.